DDL, a provider of package, product, and material testing services, announced on Monday the opening of a new Good Manufacturing Practice (GMP) laboratory for drug-device combination product testing.
This expansion enhances DDL's capacity to support the pharmaceutical, biotech and combination product industries with rigorous, regulatory-compliant testing solutions.
The new FDA-registered 10,600 sq ft GMP lab is located near DDL's headquarters in Eden Prairie, Minnesota. The lab will offer ICH stability testing, functional and mechanical performance testing (ISO 11040 & ISO 11608) and simulated distribution testing to meet the growing demand for high-quality GMP testing for devices such as auto injectors, pre-filled syringes, inhalers and other combination products.
DDL said that its new facility will provide comprehensive testing solutions in accordance with FDA, ISO and other global regulatory standards.
Organon acquires US rights to TOFIDENCE from Biogen
Oncopeptides secures FDA approval to resume OPD5 clinical development
Bonesupport submits FDA application for CERAMENT V
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
DDL opens new GMP laboratory for drug-device combination product testing
Langhua Pharmaceutical passes US FDA's on-site inspection
PTC Therapeutics announces opinion regarding Translarna's (ataluren) European renewal authorisation
Soleno Therapeutics selects PANTHERx Rare as specialty pharmacy for VYKAT XR distribution